FDA Approves Subcutaneous SKYRIZI for Crohn's Disease Induction

The FDA has approved a subcutaneous formulation of SKYRIZI (risankizumab) for the induction of Crohn's disease, providing patients with a convenient self-administered treatment option previously requiring intravenous infusion. Additionally, the FDA revised SKYRIZI's label across all indications, allowing clinicians discretion for tuberculosis testing before treatment. This approval enhances patient accessibility and convenience for managing Crohn's disease.